A University of Otago-led study has found highly vulnerable weakness in drug-resistant Mycobacterium tuberculosis, offering a new way to kill them.
Amgen scores late-stage trial success for eczema and myasthenia gravis treatments, but faces stiff competition
Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded in late-stage trials, but the therapies